MARKET

MACK

MACK

Merrimack Pharma
NASDAQ
15.13
0.00
0.00%
After Hours: 15.16 +0.03 +0.20% 19:59 05/17 EDT
OPEN
15.15
PREV CLOSE
15.13
HIGH
15.17
LOW
15.13
VOLUME
1.26M
TURNOVER
0
52 WEEK HIGH
15.89
52 WEEK LOW
11.53
MARKET CAP
219.87M
P/E (TTM)
-183.1719
1D
5D
1M
3M
1Y
5Y
Earnings week ahead: NVIDIA, Target, Zoom Video, Snowflake and more
Seeking Alpha · 1d ago
MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024
Merrimack Pharmaceuticals reported earnings per share of -3 cents for the first quarter of 2024. The company did not report any revenue for the quarter. Merrimack reported results for the second quarter of 2016. The pharmaceuticals company reported no revenue for this quarter.
Investorplace · 4d ago
Merrimack Pharmaceuticals, Inc. 10-Q Report for the Quarterly Period Ended March 31, 2024
Press release · 4d ago
Weekly Report: what happened at MACK last week (0506-0510)?
Weekly Report · 05/13 10:02
Merrimack Pharmaceuticals stockholders approve plan of dissolution
Healthcare Merrimack Pharmaceuticals stockholders approve plan of dissolution May 10, 2024. The company's common stock will delist from Nasdaq on May 20. MACK declared a liquidating cash dividend in the amount of $15.10/share to be paid on May 17.
Seeking Alpha · 05/10 20:55
Merrimack Pharmaceuticals Approves Liquidation and Dividend
TipRanks · 05/10 20:52
Merrimack Pharmaceuticals Shareholders OK Dissolution Plan
Merrimack Pharmaceuticals says shareholders approve plan of dissolution and liquidating cash dividend. Merrimack's shares will delist from the Nasdaq on May 20. The dividend will be $15.10 a share. The company sold Onivyde, a drug to treat metastatic pancreatic cancer.
Dow Jones · 05/10 20:47
Merrimack Pharmaceuticals Announces Approval Of Plan Of Dissolution And Cash Liquidating Dividend Amount Of $15.10 Per Share
Merrimack's Common Stock will trade on NASDAQ through May 17, 2024 and will delist from NASDAQ on May 20, 2024. The Board of Directors declared a liquidating cash dividend in the amount of $15.10 per share. The dividend is expected to be paid in May 2024. Merrimack shareholders overwhelmingly approved a Plan of Dissolution.
Benzinga · 05/10 20:36
More
About MACK
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. It is entitled to receive payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. These payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of Onivyde for certain additional clinical indications. ONIVYDE is approved by FDA to market as a first-line treatment of metastatic adenocarcinoma on the pancreas. It is also entitled to receive payments related to its sale of anti-HER3 programs to Elevation Oncology, Inc. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.

Webull offers Merrimack Pharmaceuticals Inc stock information, including NASDAQ: MACK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MACK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MACK stock methods without spending real money on the virtual paper trading platform.